Gastroparesis on GLP-1s: How Rare, How Serious, How to Know

If you are on semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or another GLP-1 receptor agonist, you already know the deal with nausea. It is one of the most common side effects, especially during dose escalation. Your doctor probably told you it would get better. For most people, it does. But for a smaller group, the nausea does not get better. The fullness becomes extreme. Food sits in the stomach for hours, sometimes reappearing largely undigested. That is not the expected adjustment period. That is potentially gastroparesis, and it is worth understanding the difference.

What is the difference between expected slow digestion and gastroparesis on GLP-1s?

This is probably the most important distinction in the entire GLP-1 side effect conversation. GLP-1 receptor agonists work, in part, by slowing gastric emptying. That is not a bug. It is a core feature of how these drugs reduce appetite, lower postprandial glucose spikes, and promote satiety. When you feel full sooner on Ozempic or Mounjaro, slower gastric emptying is one of the reasons.

During dose escalation, that slowing effect can be pronounced. Nausea, early fullness, occasional vomiting, and reduced appetite are all common. In clinical trials for semaglutide 2.4 mg (the Wegovy dose), nausea was reported by about 44% of participants, and vomiting by about 24% (Wilding et al., NEJM, 2021). For tirzepatide at the highest dose (15 mg), nausea hit about 31% and vomiting about 13% (Jastreboff et al., NEJM, 2022). These symptoms typically peaked during dose increases and resolved within 4 to 8 weeks at a stable dose.

Gastroparesis is different. Clinically, it is defined as objectively delayed gastric emptying (more than 10% of a standardized meal remaining in the stomach at 4 hours on scintigraphy) in the absence of a mechanical obstruction. It is not just feeling full. It is measurable, persistent impairment of the stomach's ability to move food forward.

How common is gastroparesis on GLP-1 medications?

This is where the data gets nuanced. The headline numbers depend heavily on how you define gastroparesis and which population you study. A widely cited retrospective cohort study published in JAMA in October 2023 by Sodhi et al. examined insurance claims from over 16 million patients. Among those prescribed GLP-1 agonists for weight loss (not diabetes), the adjusted hazard ratio for gastroparesis was 3.67 compared to patients on bupropion-naltrexone. The absolute risk, however, was low: roughly 10 per 10,000 person-years of use.

A 2024 pharmacovigilance analysis of the FDA's Adverse Event Reporting System (FAERS) found thousands of gastroparesis reports linked to semaglutide and tirzepatide, but FAERS data is notoriously difficult to interpret. It captures reports, not confirmed diagnoses, and it cannot establish causation or calculate true incidence. Reporting rates spike when a side effect gets media attention, which gastroparesis certainly has.

What we can say is this: gastroparesis on GLP-1s is uncommon but not vanishingly rare. It is substantially less common than ordinary nausea or vomiting. But given that tens of millions of people are now on these medications worldwide, even a small percentage translates to a meaningful number of individuals affected.

What are the warning signs of gastroparesis versus normal GLP-1 side effects?

The timing and character of symptoms are your most useful signals. Normal GLP-1 side effects tend to follow a predictable pattern: they worsen during dose escalation, improve with dose stabilization, and are generally manageable with smaller meals and slower eating. Gastroparesis breaks that pattern.

How is gastroparesis diagnosed while on a GLP-1?

The gold standard is a gastric emptying scintigraphy study (GES), sometimes called a gastric emptying scan. You eat a standardized meal (usually eggs and toast labeled with a small amount of radioactive tracer), and a gamma camera takes images at 1, 2, and 4 hours to measure how much food has left your stomach. Gastroparesis is defined as more than 10% of the meal remaining at the 4-hour mark (Camilleri et al., Gastroenterology, 2018).

There is an important catch. GLP-1 medications themselves slow gastric emptying, so a positive GES while you are actively taking the medication does not automatically mean you have gastroparesis as a disease. It might just mean the drug is doing its job. Some motility specialists recommend repeating the GES after holding the GLP-1 for a sufficient washout period (which varies by medication, see the half-life discussion below). If emptying normalizes off the drug, the issue was pharmacologic rather than pathologic.

An upper endoscopy (EGD) is often ordered but will not diagnose gastroparesis by itself. Its role is to rule out a mechanical obstruction (like a stricture or tumor) that could be causing similar symptoms. If your endoscopy is normal but symptoms persist, that does not mean nothing is wrong. It means you need a functional test like the GES.

What factors increase the risk of gastroparesis on GLP-1s?

The research here is still early, and we do not have validated risk prediction models. However, several factors appear to be clinically relevant based on case series and pharmacologic reasoning.

How is GLP-1-associated gastroparesis managed?

Management follows a stepwise approach, and the first question is always whether to adjust or stop the GLP-1 medication.

Dose reduction is the most common first step. Many patients who develop gastroparesis symptoms at higher doses (e.g., semaglutide 2.4 mg) can tolerate a lower dose (e.g., 1.0 mg) with acceptable symptom control. Your prescriber and you can weigh the trade-off between metabolic benefit and GI tolerability. For tirzepatide, the same principle applies: stepping down from 15 mg to 10 mg or even 5 mg may resolve the issue.

If dose reduction does not help, medication discontinuation is the next consideration. Because GLP-1 agonists have long half-lives (semaglutide's is approximately 7 days, tirzepatide's is about 5 days), it can take several weeks after the last injection before the drug is substantially cleared. Symptom improvement may lag behind discontinuation.

Dietary modifications during the symptomatic period include eating smaller, more frequent meals (5 to 6 per day instead of 3), favoring low-fat and low-fiber foods (both slow emptying further), choosing softer or pureed textures, and avoiding large volumes of liquid with meals. A registered dietitian experienced with gastroparesis can be very helpful here.

Prokinetic medications may be considered. Metoclopramide (Reglan) is FDA-approved for gastroparesis but carries a black box warning for tardive dyskinesia with prolonged use. Domperidone is used in many countries outside the U.S. and has a better side effect profile, though it is only available stateside through the FDA's expanded access program. Erythromycin at low doses (50 to 100 mg before meals) acts as a motilin receptor agonist and can accelerate emptying, though tachyphylaxis (the drug losing effectiveness) often occurs within weeks (Camilleri et al., AJG, 2013).

When should you stop your GLP-1 medication because of gastroparesis?

This is ultimately a decision between you and your prescriber, but certain situations make discontinuation the safer choice. If you cannot maintain adequate nutrition orally despite dietary modification, that is a clear signal. If symptoms are persisting beyond 8 to 12 weeks at a stable dose with no improvement trend, waiting longer is unlikely to change the outcome. If you are losing weight beyond what is clinically appropriate, or if you are developing complications like aspiration risk, dehydration, or electrolyte abnormalities, the medication's risks have exceeded its benefits for you specifically.

It is worth noting that stopping a GLP-1 does not guarantee immediate resolution. A subset of patients in case reports and the litigation filings describe symptoms persisting for months after discontinuation. The reasons are not fully understood but may involve prolonged receptor downregulation or unmasking of subclinical motility disorders that the medication worsened.

What helps with tracking and managing symptoms?

If you are concerned about gastroparesis, detailed symptom tracking becomes genuinely useful for both you and your clinician. Documenting what you ate, when symptoms occurred, their severity, and any relationship to dose changes creates a timeline that helps distinguish expected adjustment from pathology. Tools like GLP1Gut can help you track meal timing, symptom patterns, and medication doses so you have organized data to share with your provider rather than relying on memory.

Bringing a clear symptom timeline to your appointment can make the difference between being told 'that is normal, give it time' and getting a referral for a gastric emptying study. Clinicians respond to patterns, and patterns require data.

The bottom line on GLP-1s and gastroparesis risk

GLP-1 receptor agonists are effective medications for diabetes and obesity with a strong evidence base. Slowed gastric emptying is an intended part of how they work. For the vast majority of users, the GI side effects are temporary and manageable. But gastroparesis is a real, if uncommon, risk that deserves more attention than a footnote in a prescribing pamphlet.

Know the warning signs. Understand that a normal endoscopy does not rule it out. Ask about a gastric emptying study if your symptoms are not fitting the expected pattern. And do not let anyone dismiss persistent, severe GI symptoms as just 'part of being on Ozempic.' Sometimes it is more than that, and catching it early gives you the most options.